Abstract
BackgroundInterleukin-1 receptor antagonist (IL1RN) has been reported as a biomarker of many cancers. However, the biological function of IL1RN in papillary thyroid carcinoma (PTC) remains undetermined.MethodsWe obtained IL1RN expression data from The Cancer Genome Atlas (TCGA) database. Enrichment analysis of coexpressed genes and IL1RN methylation analysis were performed via LinkedOmics. The correlations between IL1RN and immune infiltrates were investigated via ESTIMATE, TIMER and TISIDB. We analyzed the association of IL1RN expression with pancancer overall survival (OS) via Gene Expression Profiling Interactive Analysis (GEPIA).ResultsIL1RN showed higher expression levels and lower methylation levels in PTC tissues than in normal tissues. Higher IL1RN expression was significantly associated with shorter progression-free survival (PFS), advanced tumor stage, tumor metastasis, increased incidence of BRAF mutations, and decreased incidence of N-RAS and H-RAS mutations. Genes coexpressed with IL1RN participate primarily in immune-related pathways. IL1RN expression positively correlated with immune infiltration, tumor progression and poor OS for all cancers.ConclusionsIL1RN is a good prognostic and diagnostic biomarker for PTC. IL1RN may promote thyroid cancer progression through immune-related pathways. Methylation may act as an upstream regulator of IL1RN expression and biological function. Additionally, IL1RN was shown to have broad prognostic value in a pancancer cohort.
Highlights
Interleukin-1 receptor antagonist (IL1RN) has been reported as a biomarker of many cancers
Niedzwiecki, S. and colleagues assayed the serum levels of IL1RN in thyroid cancer patients. They measured preoperative IL1RN serum levels of patients with thyroid cancer, and the results showed that the serum concentrations of The soluble extracellular form of IL1RN (sIL-1ra) were significantly higher in anaplastic carcinoma (ATC) and follicular carcinoma (FTC) patients [21]
The differential expression and diagnostic value of IL1RN The expression levels of IL1RN were initially analyzed in the The Cancer Genome Atlas (TCGA) cohort consisting of 512 papillary thyroid carcinoma (PTC) samples and 58 normal samples (Fig. 1a)
Summary
Interleukin-1 receptor antagonist (IL1RN) has been reported as a biomarker of many cancers. The biological function of IL1RN in papillary thyroid carcinoma (PTC) remains undetermined. Thyroid carcinoma (THCA) is the most common endocrine malignancy worldwide [1]. The incidence of THCA has increased sharply over the past 3 decades [2]. Papillary thyroid carcinoma (PTC) is the major subtype of THCA, accounting for more than 90% of cases [3]. The incidence of cervical lymph node metastasis is high, which leads to local recurrence and poor prognosis [5]. Further studies are required to explore the underlying mechanisms of tumorigenesis as well as identify additional biomarkers that predict prognosis and serve as therapeutic targets
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
